Onconova, SymBio in rigosertib development pact
Rigosertib is a patent protected multi-kinase inhibitor of critical pathways important in the growth and proliferation of cancer cells. As per the terms of the agreement, SymBio will
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.